Onclink Trademark Details

This mark is dead with a status of Abandoned - No Statement of Use Filed. The last case file activity for this mark occured 16 years ago on Wednesday, August 1, 2007, according to the United State Patent & Trademark Office
Word Mark Onclink
Status Dead 606 — Abandoned - No Statement of Use Filed

Current Owner

Impactrx, Inc. of Mount Laurel, NJ

View all trademarks for Impactrx, Inc.
Other Trademarks for Impactrx, Inc.
Serial Number 78665475
Status Date Wednesday, August 1, 2007
Filing Date Wednesday, August 1, 2007
Attorney Stanley H. Cohen, Esq.

Correspondent

STANLEY H. COHEN, ESQ.
CAESAR, RIVISE, BERNSTEIN, COHEN & POKOT
11TH FLOOR, SEVEN PENN CENTER
1635 MARKET STREET
PHILADELPHIA, PA 19103-2212

Case File Statements

Goods & Services Reports to Pharmaceutical Manufacturers on Market Research Results Relating to Oncology Pharmaceuticals
Goods & Services Providing to Pharmaceutical Manufacturers Business Information in the Field of Pharmaceuticals, Namely, Information on Product Volume and Marketing Activities
Pseudo Mark On Clink

Classifications

International Class Codes
016 — Class 16 includes mainly paper, goods made from that material and office requisites.
U.S. Class Codes 002, 005, 022, 023, 029, 037, 038, 050
Status 6 — Active
Status Date Tuesday, July 12, 2005
Primary Code 016
International Class Codes
035 — Class 35 includes mainly services rendered by persons or organizations principally with the object of: 1. help in the working or management of a commercial undertaking, or 2. help in the management of the business affairs or commercial functions of an industrial or commercial enterprise, as well as services rendered by advertising establishments primarily undertaking communications to the public, declarations or announcements by all means of diffusion and concerning all kinds of goods or services.
U.S. Class Codes 100, 101, 102
Status 6 — Active
Status Date Tuesday, July 12, 2005
Primary Code 035

You must be signed in to print.

Once signed in, look for the PDF button.